

Highlights of This Issue 937

SPECIAL FEATURES

CCR 20th Anniversary Commentary

- 939** CCR 20th Anniversary Commentary: In the Beginning, There Was PS-341
Beverly A. Teicher and Kenneth C. Anderson
- 942** CCR 20th Anniversary Commentary: Preclinical Study of Proteasome Inhibitor Bortezomib in Head and Neck Cancer
Clint T. Allen, Barbara Conley, John B. Sunwoo, and Carter Van Waes

CCR Translations

- 944** Immunomodulatory Antibody Therapy of Cancer: The Closer, the Better
Roxana S. Dronca and Haidong Dong
See related articles, p. 1115 and p. 1127
- 947** Moving from Evaluation to Value in Cancer Care
Richard L. Schilsky
See related article, p. 1036

CCR Perspectives in Drug Approval

- 950** FDA Approval: Siltuximab for the Treatment of Patients with Multicentric Castleman Disease
Albert Deisseroth, Chia-Wen Ko, Lei Nie, Jeanne F. Zirkelbach, Liang Zhao, Julie Bullock, Nitin Mehrotra, Pedro Del Valle, Haleh Saber, Christopher Sheth, Brenda Gehrke, Robert Justice, Ann Farrell, and Richard Pazdur

Molecular Pathways

- 955** Molecular Pathways: Translational and Therapeutic Implications of the Notch Signaling Pathway in Cancer
Rebecca A. Previs, Robert L. Coleman, Adrian L. Harris, and Anil K. Sood
- 962** Molecular Pathways: Linking Tumor Microenvironment to Epithelial–Mesenchymal Transition in Metastasis
Hae-Yun Jung, Laurent Fattet, and Jing Yang

Reviews

- 969** Zebrafish: A New Companion for Translational Research in Oncology
Jorge Barriuso, Raghavendar Nagaraju, and Adam Hurlstone
- 976** Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non–Small Cell Lung Cancer
 Valsamo K. Anagnostou and Julie R. Brahmer

CANCER THERAPY: CLINICAL


- 985** A Phase I Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes
Guillermo Garcia-Manero, Hanna J. Khoury, Elias Jabbour, Jeffrey Lancet, Shannon L. Winski, LouAnn Cable, Selena Rush, Lara Maloney, Grant Hogeland, Mieke Ptaszynski, Monica Cabrero Calvo, Zach Bohannan, Alan List, Hagop Kantarjian, and Rami Komrokji
- 995** CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb⁺ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
Angela DeMichele, Amy S. Clark, Kay See Tan, Daniel F. Heitjan, Kristi Gramlich, Maryann Gallagher, Priti Lal, Michael Feldman, Paul Zhang, Christopher Colameco, David Lewis, Melissa Langer, Noah Goodman, Susan Domchek, Keerthi Gogineni, Mark Rosen, Kevin Fox, and Peter O'Dwyer
- 1002** Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors
 Jonathan Goldman, S. Gail Eckhardt, Mitesh J. Borad, Kelly K. Curtis, Manuel Hidalgo, Emiliano Calvo, David P. Ryan, Lori J. Wirth, Asit Parikh, James Partyka, Helene Faessel, Esha Gangolli, Sally Stewart, Lee S. Rosen, and Daniel W. Bowles
- 1010** Angiogenic Cytokines Are Antibody Targets During Graft-versus-Leukemia Reactions
Matthias Piesche, Vincent T. Ho, Haesook Kim, Yukoh Nakazaki, Michael Nehil, Nasser K. Yaghi, Dmitriy Kolodin, Jeremy Weiser, Peter Altevogt, Helena Kiefel, Edwin P. Alyea, Joseph H. Antin, Corey Cutler, John Koreth, Christine Canning, Jerome Ritz, Robert J. Soiffer, and Glenn Dranoff

Table of Contents

1019 A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

Paul F. Robbins, Sadik H. Kassim, Thai L.N. Tran, Jessica S. Crystal, Richard A. Morgan, Steven A. Feldman, James C. Yang, Mark E. Dudley, John R. Wunderlich, Richard M. Sherry, Udai S. Kammula, Marybeth S. Hughes, Nicholas P. Restifo, Mark Raffeld, Chyi-Chia R. Lee, Yong F. Li, Mona El-Gamil, and Steven A. Rosenberg

1028 Redifferentiation of Iodine-Refractory *BRAF* V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib

S. Michael Rothenberg, David G. McFadden, Edwin L. Palmer, Gilbert H. Daniels, and Lori J. Wirth

1036 Raising the Bar for Antineoplastic Agents: How to Choose Threshold Values for Superiority Trials in Advanced Solid Tumors

Alberto F. Sobrero, Alessandro Pastorino, Daniel J. Sargent, and Paolo Bruzzi
See related commentary, p. 947

1044 A Phase I Study of PF-04449913, an Oral Hedgehog Inhibitor, in Patients with Advanced Solid Tumors



Andrew J. Wagner, Wells A. Messersmith, M. Naveed Shaik, Sherry Li, Xianxian Zheng, Karen R. McLachlan, Rossano Cesari, Rachel Courtney, Wendy J. Levin, and Anthony B. El-Khoueiry

PERSONALIZED MEDICINE AND IMAGING

1052 Nottingham Clinico-Pathological Response Index (NPRI) after Neoadjuvant Chemotherapy (Neo-ACT) Accurately Predicts Clinical Outcome in Locally Advanced Breast Cancer

Tarek M. Abdel-Fatah, Graham Ball, Andrew H.S. Lee, Sarah Pinder, R. Douglas MacMilan, Eleanor Cornford, Paul M. Moseley, Rafael Silverman, James Price, Bruce Latham, David Palmer, Arlene Chan, Ian O. Ellis, and Stephen Y.T. Chan

1063 Longitudinal Noninvasive Imaging of Progesterone Receptor as a Predictive Biomarker of Tumor Responsiveness to Estrogen Deprivation Therapy

Szeman Ruby Chan, Amy M. Fowler, Julie A. Allen, Dong Zhou, Carmen S. Dence, Terry L. Sharp, Nicole M. Fettig, Farrokh Dehdashti, and John A. Katzenellenbogen

1071 Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial

Toni K. Choueiri, David J. Figuroa, André P. Fay, Sabina Signoretti, Yuan Liu, Robert Gagnon, Keith Deen, Christopher Carpenter, Peter Benson, Thai H. Ho, Lini Pandite, Paul de Souza, Thomas Powles, and Robert J. Motzer

1078 Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results from CALGB 80203 (Alliance)

Stephanie M. Cushman, Chen Jiang, Ace J. Hatch, Ivo Shterev, Alexander B. Sibley, Donna Niedzwiecki, Alan P. Venook, Kouros Owzar, Herbert I. Hurwitz, and Andrew B. Nixon

1087 Clinical Relevance of *KRAS*-Mutated Subclones Detected with Picodroplet Digital PCR in Advanced Colorectal Cancer Treated with Anti-EGFR Therapy

Pierre Laurent-Puig, Deniz Pekin, Corinne Normand, Steve K. Kotsopoulos, Philippe Nizard, Karla Perez-Toralla, Rachel Rowell, Jeff Olson, Preethi Srinivasan, Delphine Le Corre, Theyv Hor, Zakaria El Harrak, Xinyu Li, Darren R. Link, Olivier Bouché, Jean-François Emile, Bruno Landi, Valérie Boige, J. Brian Hutchison, and Valerie Taly

1098 Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers

Mark Jesus M. Magbanua, Lisa A. Carey, Amy DeLuca, Jimmy Hwang, Janet H. Scott, Mothaffar F. Rimawi, Erica L. Mayer, P. Kelly Marcom, Minetta C. Liu, Francisco J. Esteva, John W. Park, and Hope S. Rugo for the Translational Breast Cancer Research Consortium

1106 Neuregulin 1 Expression Is a Predictive Biomarker for Response to AV-203, an ERBB3 Inhibitory Antibody, in Human Tumor Models



Kristan Meetze, Sylvie Vincent, Steven Tyler, Elizabeth K. Mazsa, Andrea R. Delpero, Steve Bottega, Donna McIntosh, Richard Nicoletti, William M. Winston, Solly Weiler, Bin Feng, Jenö Gyuris, and Zhigang Weng

CANCER THERAPY: PRECLINICAL

1115 The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell-Dependent Tumor Immunity




Sara M. Mangsbo, Sissela Broos, Erika Fletcher, Niina Veitonmäki, Christina Furebring, Eva Dahlén, Per Norlén, Malin Lindstedt, Thomas H. Tötterman, and Peter Ellmark

See related commentary, p. 944

Table of Contents


1127 Curing Mice with Large Tumors by Locally Delivering Combinations of Immunomodulatory Antibodies
Min Dai, Yuen Yee Yip, Ingegerd Hellstrom, and Karl Erik Hellstrom
See related commentary, p. 944

1139 Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High *SLFN11* Expression
Min H. Kang, Jing Wang, Monish R. Makena, Joo-Sang Lee, Nancy Paz, Connor P. Hall, Michael M. Song, Ruben I. Calderon, Riza E. Cruz, Ashly Hindle, Winford Ko, Jonathan B. Fitzgerald, Daryl C. Drummond, Timothy J. Triche, and C. Patrick Reynolds

1151  Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects
Catharina M.L. Zegers, Nicolle H. Rekers, Dana H.F. Quaden, Natasja G. Lieuwes, Ala Yaromina, Wilfred T.V. Germeraad, Lotte Wieten, Erik A.L. Biessen, Louis Boon, Dario Neri, Esther G.C. Troost, Ludwig J. Dubois, and Philippe Lambin

1161 Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin
Sevim Dalva-Aydemir, Richa Bajpai, Maylyn Martinez, Kehinde U.A. Adekola, Irawati Kandela, Changyong Wei, Seema Singhal, Jennifer E. Koblinski, Noopur S. Rajee, Steven T. Rosen, and Mala Shanmugam

1172 Patient-Derived Xenografts from Non-Small Cell Lung Cancer Brain Metastases Are Valuable Translational Platforms for the Development of Personalized Targeted Therapy
Hye Won Lee, Jung-il Lee, Se Jeong Lee, Hyun Jung Cho, Hye Jin Song, Da Eun Jeong, Yun Jee Seo, Sang Shin, Je-Gun Joung, Yong-Jun Kwon, Yoon-La Choi, Woong-Yang Park, Hyun Moo Lee, Ho Jun Seol, Young Mog Shim, Kyeung Min Joo, and Do-Hyun Nam

1183  Integrin β 6-Targeted Immunoliposomes Mediate Tumor-Specific Drug Delivery and Enhance Therapeutic Efficacy in Colon Carcinoma
Benjia Liang, Muhammad Shahbaz, Yang Wang, Huijie Gao, Ruliang Fang, Zhengchuan Niu, Song Liu, Ben Wang, Qi Sun, Weibo Niu, Enyu Liu, Jiayong Wang, and Jun Niu

BIOLOGY OF HUMAN TUMORS

1196 Epigenetics Markers of Metastasis and HPV-Induced Tumorigenesis in Penile Cancer
Andrew Feber, Manit Arya, Patricia de Winter, Muhammad Saqib, Raj Nigam, Peter R. Malone, Wei Shen Tan, Simon Rodney, Matthias Lechner, Alex Freeman, Charles Jameson, Asif Muneer, Stephan Beck, and John D. Kelly

1207 A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients
Kristine Kleivi Sahlberg, Giulia Bottai, Bjørn Naume, Barbara Burwinkel, George A. Calin, Anne-Lise Børresen-Dale, and Libero Santarpia

1215 Sonic Hedgehog and Gli1 Expression Predict Outcome in Resected Pancreatic Adenocarcinoma
Raphaël Maréchal, Jean-Baptiste Bachet, Annabelle Calomme, Pieter Demetter, Jean Robert Delpero, Magali Svrcek, Jérôme Cros, Armelle Bardier-Dupas, Francesco Puleo, Geneviève Monges, Pascal Hammel, Christophe Louvet, François Paye, Philippe Bachelier, Yves Patrice Le Treut, Jean-Christophe Vaillant, Alain Sauvanet, Thierry André, Isabelle Salmon, Jacques Devière, Jean-François Emile, and Jean-Luc Van Laethem

1225 Direct Serum Assay for Cell-Free *Bmi-1* mRNA and Its Potential Diagnostic and Prognostic Value for Colorectal Cancer
Xin Zhang, Xiaoyun Yang, Yanli Zhang, Xinfeng Liu, Guixi Zheng, Yongmei Yang, Lili Wang, Lutao Du, and Chuanxin Wang

 AC icon indicates Author Choice

 CME icon indicates that this article is available for continuing medical education credit at <http://cme.aacrjournals.org>

For more information please visit www.aacrjournals.org

Table of Contents

ABOUT THE COVER

The cover shows a section of a tumor biopsy from mice with the SW1 melanoma, which were treated with an anti-CTLA4/PD-1/CD137 mAb combination. Immunohistochemical staining shows a dramatic decrease of tumor-infiltrating CD19 cells. For details, see the article by Dai and colleagues on page 1127 of this issue.



Clinical Cancer Research

21 (5)

Clin Cancer Res 2015;21:937-1233.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/21/5>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/21/5>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.